A pan-cancer analysis demonstrated that tumors with genetic activation of NRF2 exhibit qualities of enhanced immunoevasion including enrichment of MHC-I mutations, reduced immune infiltration, and suppression of activating ligands for NK cells [59]. Here, NFE2L2 is linked to cancer.